Oophorectomy

Return to Freedom: BLM should not pursue sterilization of wild mares

Retrieved on: 
Monday, March 18, 2024
Congress, Growth, Infection, AML, Horse, BLM, Education, Sterilization, Bureau, Rest, Death, Oophorectomy, RTF, Behavior, Bleeding, Culdocentesis, Wild horse, Animal, Fiscal, Birth control

LOMPOC, Calif., March 18, 2024 /PRNewswire/ -- Return to Freedom Wild Horse Conservation announced on Monday that it will remain vigilant that the Bureau of Land Management (BLM) not again pursue the invasive surgical sterilization of wild mares.

Key Points: 
  • LOMPOC, Calif., March 18, 2024 /PRNewswire/ -- Return to Freedom Wild Horse Conservation announced on Monday that it will remain vigilant that the Bureau of Land Management (BLM) not again pursue the invasive surgical sterilization of wild mares.
  • The BLM shouldn't make yet another wrong turn, and Congress should not enable it," said Neda DeMayo, president of Return to Freedom (RTF), a national nonprofit wild horse and burro advocacy organization.
  • When the BLM has pursued surgical sterilization of mares, it has been halted by litigation and public opposition.
  • Return to Freedom Wild Horse Conservation (RTF ) is a national nonprofit organization dedicated to wild horse preservation through sanctuary, education, conservation, and advocacy since 1998.

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Retrieved on: 
Wednesday, August 10, 2022
Teriparatide, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Risk, Global Investment in American Jobs Act of 2013, Injection, Name, Industry, Forward-looking statement, Octreotide, Cmax, Private Securities Litigation Reform Act, IP, SEC, Synthetic control method, Securities Exchange Act of 1934, PD, Security (finance), SC, Oophorectomy, Therapy, COVID-19, OVX, Â, Abaloparatide, DS, Safety, Automation, AUC, PK, PTH, Publication, BMD, Securities Act of 1933, Time, HC, Jumpstart Our Business Startups Act, Osteoporosis, Terminology, Generic drug, Dietary supplement, Pharmaceutical industry

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human parathyroid hormone (PTH) analog PTH (1-34) for the potential treatment of osteoporosis (“Study Part 1”). Study Part 1 achieved all of its endpoints, with RT-102 being generally well-tolerated and demonstrating high oral bioavailability of Rani’s PTH analog.

Key Points: 
  • The study found that, following six weeks of treatment:
    RT-102 DS increased BMD in a rat model of osteoporosis.
  • RT-102 DS delivered via the RaniPill IP route of administration was biologically active comparable to SC injected PTH analogs.
  • Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics.
  • Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsules.

Zoledronic Acid and Post-Menopausal Osteoporosis

Retrieved on: 
Wednesday, August 11, 2021
Hospital, Osteoblast, Bone loss, Bone resorption, Zoledronic acid, Osteoporosis, Breast implant, Risk, Mandible, Experimental biology, Experimental Biology and Medicine, Menopause, Publishing, Society, Oophorectomy, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Prosthodontics, NF, Implant, Cell, Apoptosis, Fracture, Multimedia, RATS, Osteoclast, Woman, Guizhou Medical University, Dentistry

Zoledronic acid inhibits bone resorption and is an effective treatment for osteoporosis.

Key Points: 
  • Zoledronic acid inhibits bone resorption and is an effective treatment for osteoporosis.
  • Nonetheless, the effects of zoledronic acid on bones involved in dental implant procedures and bone cells have not been fully elucidated.
  • In this study, Yu-Ting Cheng and colleagues examined the effects of zoledronic acid on bone cells in an animal model of osteoporosis, ovariectomized rats that do not produce estrogen.
  • Our study suggests that low-dose zoledronic acid may inhibit mandibular resorption by inhibiting the NF-B signal pathway.We are currently examining the specific site of action, phosphorylation events, and downstream effector molecules for zoledronic acid."

FDA Authorizes First Robotically-Assisted Surgical Device for Performing Transvaginal Hysterectomy

Retrieved on: 
Monday, March 1, 2021
Medicine, Clinical medicine, Medical specialties, Gynecological surgery, Oophorectomy, Hysterectomy, Fallopian tube, Uterus, Salpingoophorectomy, Salpingectomy, Robot-assisted surgery

SILVER SPRING, Md., March 1, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients.

Key Points: 
  • SILVER SPRING, Md., March 1, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients.
  • The Hominis Surgical System is intended for benign hysterectomy (removal of the uterus for non-cancerous conditions) with salpingo-oophorectomy (removal of one or both fallopian tubes and ovaries).
  • "The FDA continues to support advancements in safe and effective medical devices that can improve patient experiences when undergoing surgical procedures."
  • RASD, sometimes referred to as robotic surgical devices or computer-assisted surgical devices, are not actually robots.

Mercy Medical Center's Dr. Dwight Im One of Only Two U.S. Surgeons to Perform Livestreamed Surgery as part of International AAGL Conference

Retrieved on: 
Thursday, November 5, 2020
Medicine, Clinical medicine, Medical specialties, Gynaecology, Gynecological surgery, AAGL, Endoscopy, Laparoscopy, Hysterectomy, Oophorectomy, Minimally invasive procedure, Alexander Gershman

This year's event is entitled, AAGL 2020 VIRTUAL 49th GLOBAL CONFERENCE on MIGS (Minimally Invasive Gynecologic Surgery) and runs Friday, Nov. 6th through Saturday, Nov. 14th.

Key Points: 
  • This year's event is entitled, AAGL 2020 VIRTUAL 49th GLOBAL CONFERENCE on MIGS (Minimally Invasive Gynecologic Surgery) and runs Friday, Nov. 6th through Saturday, Nov. 14th.
  • Dr. Im will perform a robot-assisted laparoscopic modified radical hysterectomy with bilateral pelvic lymphadenectomy from the operating theater at Mercy Medical Center in downtown Baltimore, Friday, Nov. 13th, 11 a.m.-2 p.m. EST.
  • Dr. Im will provide a live surgical demonstration of robot-assisted laparoscopic modified radical hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic lymphadenectomy using a technique called IMSWAY.
  • AAGL is an international professional medical association of laparoscopic surgeons and the global leader in minimally invasive gynecologic surgery.

Vasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe Pharma

Retrieved on: 
Monday, March 16, 2020
Human development, Menopause, RTT, Middle age, Endocrinology, Menstrual cycle, Hot flash, Ro, Oophorectomy

Some key highlights from the report:

Key Points: 
  • Some key highlights from the report:
    The total prevalent population of Vasomotor Symptoms associated with post menopause in 7MM countries was 41,096,968 in 2017.
  • The United States has the highest prevalent population of Hot Flashes associated with Post Menopause of 18,926,632 cases in 2017.
  • Among the 7MM, the US accounts for the 61% USD of the overall market size of Hot Flashes Associated with Post-Menopause in 2017.
  • The launch of the emerging therapies is expected to impact the Vasomotor Symptoms treatment market scenario in the upcoming years:-

Vasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe Pharma

Retrieved on: 
Monday, March 16, 2020
Human development, Menopause, RTT, Middle age, Endocrinology, Menstrual cycle, Hot flash, Ro, Oophorectomy

Some key highlights from the report:

Key Points: 
  • Some key highlights from the report:
    The total prevalent population of Vasomotor Symptoms associated with post menopause in 7MM countries was 41,096,968 in 2017.
  • The United States has the highest prevalent population of Hot Flashes associated with Post Menopause of 18,926,632 cases in 2017.
  • Among the 7MM, the US accounts for the 61% USD of the overall market size of Hot Flashes Associated with Post-Menopause in 2017.
  • The launch of the emerging therapies is expected to impact the Vasomotor Symptoms treatment market scenario in the upcoming years:-

Introducing EQUELLE®: A New Non-Hormonal Supplement for Menopause Symptom Relief†

Retrieved on: 
Thursday, April 11, 2019
Endocrine system, Menopause, Human development, Health, Menstrual cycle, Hot flash, Midwifery, Equol, Conjugated estrogens, Oophorectomy

"The exciting news is that there isnow a newnon-hormonal alternativefor women that improves boththe frequency of hot flashes and muscle aches associated with menopause."

Key Points: 
  • "The exciting news is that there isnow a newnon-hormonal alternativefor women that improves boththe frequency of hot flashes and muscle aches associated with menopause."
  • Menopause, a natural process that a woman's body experiences, can take up to seven years.
  • Once a woman has gone a whole year without a menstrual cycle, she has officially hit menopause.
  • A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol non-producing postmenopausal Japanese women.